| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3340287 | Allergologia et Immunopathologia | 2007 | 5 Pages |
Abstract
Infliximab improved joint inflammatory indexes and clinical assessments. This improvement increased the quality of life of the patients and their families, suggesting that the use of biological therapy is a good option in refractory JIA.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
X. Norambuena R., J. Mallol, G. RÃos M., F. Quevedo R., A. Quezada L.,